Wuhan Humanwell Healthcare (Group) Co., Ltd.

Humanwell Healthcare (Group) Co. Ltd. is a leading listed Chinese pharmaceutical company mainly engaged in the development, manufacture and distribution of drugs in the fields of anesthesia and analgesics, gynecological diseases, central nervous system, dermatology and respiratory diseases as well as other drugs used in hospitals. Humanwell has more than 520 approved drugs worldwide and 350 drug candidates in the pipeline. In 2022, Humanwell generated sales of USD 3.4 billion and a net profit of USD 0.38 billion. Humanwell distributes its products mainly in China, Africa and the USA and exports its products to more than 50 countries. *

	Start	2012-03-22 existent
	Group	Humanwell Healthcare (Group)
	Industry	pharmaceutical
	Industry 2	medical device

	City	n. a. Wuhan
		Address record changed: 2012-04-03

Basic data	Employees	n. a.
	Currency	USD
	Annual sales	3,400,000,000 (sales, consolidated (2022) 2022-12-31)
	Profit	380,000,000 (2022-12-31)

		* Document for »About Section«: Paion AG. (12/22/23). "Press Release: Sale of the Business Operations". Aachen.

		Record changed: 2023-12-23

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Humanwell Healthcare (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)